 Connection
Michael Szarek to Simvastatin
This is a "connection" page, showing publications Michael Szarek has written about Simvastatin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.552 |
|
|
|
-
Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol. 2010 Aug 01; 106(3):354-9.
Score: 0.338
-
Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. Eur J Cardiovasc Prev Rehabil. 2009 Jun; 16(3):315-20.
Score: 0.078
-
Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol. 2009 Mar 01; 103(5):577-82.
Score: 0.076
-
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16; 294(19):2437-45.
Score: 0.061
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|